Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: jack w garnes jr. who wrote (7854)	5/6/1998 2:32:00 PM
From: Gene Voss	Read Replies (1) \| Respond to of 23519

I have seen your extremely insightful posts on the HVSF thread.The assumption that an oral agent is preferable is obvious but assumes equal safety and efficacy to other modalities.If you have some specific insight reference it otherwise don't waste everyones time with your ravings. Incidentally I have some first hand knowledge of a patient who responded with the 100mg dose only to have experience syncope and extreme blurred vision on his 2nd exposure.This is only anecdotal but I discussed this with him in detail.Incidentally he experienced no erectile effect with the 100mg dose on his 2nd exposure.He has a history of ED of unknown etiology but is otherwise very healthy.I expect similar experiences to begin to appear as the uncontrolled use of this agent continues. GV